The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus
Objectives To investigate whether bortezomib, a proteasome inhibitor approved for treatment of multiple myeloma, induces clinically relevant plasma cell (PC) depletion in patients with active, refractory systemic lupus erythematosus (SLE). Methods Twelve patients received a median of two (range 1-4)...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
July 2015
|
| In: |
Annals of the rheumatic diseases
Year: 2015, Volume: 74, Issue: 7, Pages: 1474-1478 |
| ISSN: | 1468-2060 |
| DOI: | 10.1136/annrheumdis-2014-206016 |
| Online Access: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1136/annrheumdis-2014-206016 Verlag, kostenfrei, Volltext: http://ard.bmj.com/content/74/7/1474 
|
| Author Notes: | Tobias Alexander, Ramona Sarfert, Jens Klotsche, Anja A. Kühl, Andrea Rubbert-Roth, Hannes-Martin Lorenz, Jürgen Rech, Bimba F. Hoyer, Qingyu Cheng, Aderajew Waka, Adriano Taddeo, Michael Wiesener, Georg Schett, Gerd-Rüdiger Burmester, Andreas Radbruch, Falk Hiepe, Reinhard E. Voll |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1556324219 | ||
| 003 | DE-627 | ||
| 005 | 20230426153652.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 170405s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/annrheumdis-2014-206016 |2 doi | |
| 035 | |a (DE-627)1556324219 | ||
| 035 | |a (DE-576)486324214 | ||
| 035 | |a (DE-599)BSZ486324214 | ||
| 035 | |a (OCoLC)1340969223 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Alexander, Tobias |e VerfasserIn |0 (DE-588)1129292959 |0 (DE-627)883913194 |0 (DE-576)486323781 |4 aut | |
| 245 | 1 | 4 | |a The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus |c Tobias Alexander, Ramona Sarfert, Jens Klotsche, Anja A. Kühl, Andrea Rubbert-Roth, Hannes-Martin Lorenz, Jürgen Rech, Bimba F. Hoyer, Qingyu Cheng, Aderajew Waka, Adriano Taddeo, Michael Wiesener, Georg Schett, Gerd-Rüdiger Burmester, Andreas Radbruch, Falk Hiepe, Reinhard E. Voll |
| 264 | 1 | |c July 2015 | |
| 300 | |a 5 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 05.04.2017 | ||
| 520 | |a Objectives To investigate whether bortezomib, a proteasome inhibitor approved for treatment of multiple myeloma, induces clinically relevant plasma cell (PC) depletion in patients with active, refractory systemic lupus erythematosus (SLE). Methods Twelve patients received a median of two (range 1-4) 21-day cycles of intravenous bortezomib (1.3 mg/m2) with the coadministration of dexamethasone (20 mg) for active SLE. Disease activity was assessed using the SLEDAI-2K score. Serum concentrations of anti-double-stranded DNA (anti-dsDNA) and vaccine-induced protective antibodies were monitored. Flow cytometry was performed to analyse peripheral blood B-cells, PCs and Siglec-1 expression on monocytes as surrogate marker for type-I interferon (IFN) activity. Results Upon proteasome inhibition, disease activity significantly declined and remained stable for 6 months on maintenance therapies. Nineteen treatment-emergent adverse events occurred and, although mostly mild to moderate, resulted in treatment discontinuation in seven patients. Serum antibody levels significantly declined, with greater reductions in anti-dsDNA (∼60%) than vaccine-induced protective antibody titres (∼30%). Bortezomib significantly reduced the numbers of peripheral blood and bone marrow PCs (∼50%), but their numbers increased between cycles. Siglec-1 expression on monocytes significantly declined. Conclusions These findings identify proteasome inhibitors as a putative therapeutic option for patients with refractory SLE by targeting PCs and type-I IFN activity, but our results must be confirmed in controlled trials. | ||
| 650 | 4 | |a Autoimmune Diseases | |
| 650 | 4 | |a Autoimmunity | |
| 650 | 4 | |a B cells | |
| 650 | 4 | |a Systemic Lupus Erythematosus | |
| 650 | 4 | |a Treatment | |
| 700 | 1 | |a Lorenz, Hanns-Martin |d 1962- |e VerfasserIn |0 (DE-588)112253865 |0 (DE-627)627277845 |0 (DE-576)167601369 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of the rheumatic diseases |d [Amsterdam] : Elsevier, 1939 |g 74(2015), 7, Seite 1474-1478 |w (DE-627)300184999 |w (DE-600)1481557-6 |w (DE-576)078941237 |x 1468-2060 |7 nnas |a The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus |
| 773 | 1 | 8 | |g volume:74 |g year:2015 |g number:7 |g pages:1474-1478 |g extent:5 |a The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/annrheumdis-2014-206016 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://ard.bmj.com/content/74/7/1474 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20170405 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 112253865 |a Lorenz, Hanns-Martin |m 112253865:Lorenz, Hanns-Martin |d 910000 |d 910100 |e 910000PL112253865 |e 910100PL112253865 |k 0/910000/ |k 1/910000/910100/ |p 6 | ||
| 999 | |a KXP-PPN1556324219 |e 2964107971 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"July 2015","dateIssuedKey":"2015"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"doi":["10.1136/annrheumdis-2014-206016"],"eki":["1556324219"]},"language":["eng"],"person":[{"role":"aut","given":"Tobias","family":"Alexander","display":"Alexander, Tobias"},{"role":"aut","display":"Lorenz, Hanns-Martin","family":"Lorenz","given":"Hanns-Martin"}],"title":[{"title_sort":"proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus"}],"physDesc":[{"extent":"5 S."}],"relHost":[{"language":["eng"],"id":{"eki":["300184999"],"issn":["1468-2060"],"zdb":["1481557-6"]},"corporate":[{"role":"isb","display":"European League against Rheumatism"},{"display":"British Medical Association","role":"isb"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"ARD"}],"title":[{"title":"Annals of the rheumatic diseases","subtitle":"the EULAR journal","title_sort":"Annals of the rheumatic diseases"}],"part":{"issue":"7","year":"2015","extent":"5","pages":"1474-1478","text":"74(2015), 7, Seite 1474-1478","volume":"74"},"origin":[{"dateIssuedKey":"2025","publisher":"Elsevier ; BMJ Publ. Group","publisherPlace":"[Amsterdam] ; London","dateIssuedDisp":"2025-"}],"name":{"displayForm":["European Alliance of Associations for Rheumatology (EULAR)"]},"pubHistory":["1.1939 -"],"note":["Gesehen am 24.01.2025","Beteil. Urh. teils: British Medical Association"],"recId":"300184999","disp":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosusAnnals of the rheumatic diseases"}],"name":{"displayForm":["Tobias Alexander, Ramona Sarfert, Jens Klotsche, Anja A. Kühl, Andrea Rubbert-Roth, Hannes-Martin Lorenz, Jürgen Rech, Bimba F. Hoyer, Qingyu Cheng, Aderajew Waka, Adriano Taddeo, Michael Wiesener, Georg Schett, Gerd-Rüdiger Burmester, Andreas Radbruch, Falk Hiepe, Reinhard E. Voll"]},"note":["Gesehen am 05.04.2017"],"recId":"1556324219"} | ||
| SRT | |a ALEXANDERTPROTEASOME2015 | ||